Jonathan P. Orme

AstraZeneca (Australia) — Australia

Medicine · Health Sciences

10h-index771citations39works6.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(22), HER2/EGFR in Cancer Research(12), PARP inhibition in cancer therapy(9), Colorectal Cancer Treatments and Studies(8), Cancer therapeutics and mechanisms(6)

Publications39 total

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
Cell Reports Medicine·2025Open Access
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations
Journal of Medicinal Chemistry·2025· 5 cited
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
Journal of Medicinal Chemistry·2024· 22 cited
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
Journal of Medicinal Chemistry·2024· 3 cited
Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR
ACS Medicinal Chemistry Letters·2024· 2 citedOpen Access
CLANet: A comprehensive framework for cross-batch cell line identification using brightfield images
Medical Image Analysis·2024· 4 citedOpen Access
CLANet: A Comprehensive Framework for Cross-Batch Cell Line Identification Using Brightfield Images
arXiv (Cornell University)·2023· 1 citedOpen Access
Data from Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
2023Open Access
Data from Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
2023Open Access
Data from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Figure S1, Figure S2, Figure S3 from Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
2023Open Access
Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Data from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Figure S1, Figure S2, Figure S3 from Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
2023Open Access
Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
2023Open Access
Abstract 6302: Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper
Cancer Research·2022· 1 cited
An automated cell line authentication method for AstraZeneca global cell bank using deep neural networks on brightfield images
Scientific Reports·2022· 4 citedOpen Access
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Journal of Medicinal Chemistry·2021· 131 citedOpen Access
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
Journal of Medicinal Chemistry·2021· 31 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Nicolas Floc’h(21), Darren A.E. Cross(18), Anna D. Staniszewska(16), Richard A. Ward(16), Nicola Colclough(14), Daniel O’Neill(13), Darren McKerrecher(13), Matthew J. Martin(12), M. Raymond V. Finlay(12), Lisa McWilliams(10), Verity Talbot(9), Jeffrey W. Johannes(8), Michał Biśta(8), Giuditta Illuzzi(8), Elisabetta Leo(8), Fiona Pachl(8), Martin J. Packer(8), Sue Bickerton(8), Sébastien L. Degorce(7), Kevin J. Embrey(7)